ストックスクリーナーアプリを入手
0.5989
0.34%
-0.0089
Galmed Pharmaceuticals Ltd (GLMD) 最新ニュース
Tissue Dynamics, Galmed partner on cardiac fibrosis model By Investing.com - Investing.com Canada
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics - PR Newswire
Tissue Dynamics and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announce a strategic collaboration to jointly develop a chronic cardiac fibrosis research platform focused on human disease models. - Bitget
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Most Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed partners with Tel Aviv University on brain cancer therapy - Investing.com
Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer - TipRanks
Galmed (NASDAQ: GLMD) and Tel Aviv University test Aramchol for brain cancer - Stock Titan
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PR Newswire
GLMD SEC FilingsGalmed Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Galmed stock soars on brain-penetrating Aramchol formulation - MSN
Galmed Stock Soars On Brain-Penetrating Aramchol FormulationGalmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases - TipRanks
Galmed Pharmaceuticals Maps Future with Aramchol Strategy - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - The AI Journal
Is Galmed Pharmaceuticals (GLMD) Stock a Safe Investment | Price at $0.52, Down 1.03%Diversification - Newser
[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan
Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan
MEDIA ADVISORY – Minister LeBlanc, Secretary of State Long and Parliamentary Secretary Myles to highlight investments supporting the Canadian Armed Forces following achievement of the NATO 2% defence spending target - Weekly Voice
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - ChartMill
Ideas Watch: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2026 Update & Entry and Exit Point Strategies - baoquankhu1.vn
Portfolio Update: Can Galmed Pharmaceuticals Ltd grow without dilution2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Sectors Review: Can Galmed Pharmaceuticals Ltd deliver consistent dividendsMarket Rally & Low Risk Growth Stock Ideas - baoquankhu1.vn
Galmed (GLMD) director David Sidransky reports initial share and option holdings - Stock Titan
Galmed (GLMD) CFO details Ordinary Share, option and RSU holdings - Stock Titan
[Form 3] Galmed Pharmaceuticals Ltd. In... - Stock Titan
Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs - stocktitan.net
Galmed Pharmaceuticals Ltd. (GLMD) CSO details option holdings - Stock Titan
Galmed (GLMD) director Amir Poshinski details shares, RSUs and options - Stock Titan
Galmed Pharmaceuticals (GLMD) director Nir Shmuel details initial share and RSU holdings - Stock Titan
Aug Chart Watch: Will Galmed Pharmaceuticals Ltd. stock maintain dividend yieldShort Setup & Advanced Swing Trade Entry Plans - Naître et grandir
Smart Money: Is Galmed Pharmaceuticals Ltd stock a good dividend stockMarket Growth Review & Reliable Price Breakout Signals - baoquankhu1.vn
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Shareholders Approve Proposal at Special Meeting - The Globe and Mail
Galmed Pharmaceuticals (NASDAQ: GLMD) shareholders back proposal at March 5 special meeting - Stock Titan
Galmed Pharmaceuticals Adjourns Special Shareholder Meeting for Lack of Quorum - TipRanks
Galmed Pharmaceuticals (GLMD) adjourns shareholder meeting and resets date - Stock Titan
GLMD.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLMD Should I Buy - Intellectia AI
Buyout Rumor: Will Galmed Pharmaceuticals Ltd benefit from government policyWeekly Trend Report & Fast Momentum Entry Tips - baoquankhu1.vn
GLMD PE Ratio & Valuation, Is GLMD Overvalued - Intellectia AI
Can Galmed Pharmaceuticals Ltd. ride the EV waveWeekly Trend Recap & Daily Profit Focused Screening - mfd.ru
Why Galmed Pharmaceuticals Ltd. (GPH) stock is a must watch tickerTrade Ideas & Comprehensive Market Scan Reports - mfd.ru
Dip Buying: Why Galmed Pharmaceuticals Ltd. (GPH) stock is a must watch tickerTrade Risk Assessment & Stepwise Swing Trade Plans - mfd.ru
Can Galmed Pharmaceuticals Ltd. deliver consistent dividends2025 Price Targets & Long-Term Growth Portfolio Plans - mfd.ru
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):